PureTech Regulatory News (PRTC)

PureTech Information

Buy PRTC Shares
Add PRTC to Watchlist
Add PRTC to Alert

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 225.50

Bid: 226.00

Ask: 226.50

Change: 0.00 (0.00%)

Spread: 0.50 (0.221%)

Open: 228.00

High: 228.00

Low: 224.50

Prev. Close: 225.50

Last checked at -

Transaction in Own Shares

11 Dec 2023 07:00

RNS Number : 2496W

PureTech Health PLC

11 December 2023

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	08 December 2023

Number of ordinary shares purchased:	57,808

Highest price paid per share:	143.00p

Lowest price paid per share:	140.40p

Volume weighted average price paid per share:	141.79p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,063,635 ordinary shares in treasury and has 272,404,524 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 272,404,524 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
08/12/2023	09:30:14	249	142.4	AQXE	00381556432TRLO0.1.1
08/12/2023	09:30:14	249	142.4	AQXE	00381556433TRLO0.1.1
08/12/2023	09:30:14	387	142.4	BATE	00381556434TRLO0.1.1
08/12/2023	09:30:14	387	142.4	BATE	00381556435TRLO0.1.1
08/12/2023	09:30:14	387	142.4	CHIX	00381556436TRLO0.1.1
08/12/2023	09:30:14	139	142.4	TRQX	00381556437TRLO0.1.1
08/12/2023	09:30:14	139	142.4	TRQX	00381556438TRLO0.1.1
08/12/2023	09:30:14	1161	142.4	XLON	00381556439TRLO0.1.1
08/12/2023	09:30:14	699	142.4	XLON	00381556440TRLO0.1.1
08/12/2023	09:31:06	15	141.2	CHIX	00381556541TRLO0.1.1
08/12/2023	09:31:08	372	141.2	CHIX	00381556550TRLO0.1.1
08/12/2023	09:31:08	385	141.2	XLON	00381556551TRLO0.1.1
08/12/2023	09:31:08	776	141.2	XLON	00381556552TRLO0.1.1
08/12/2023	10:57:40	559	142.8	XLON	00381569766TRLO0.1.1
08/12/2023	11:43:39	559	142.8	XLON	00381575865TRLO0.1.1
08/12/2023	11:43:42	2944	143	XLON	00381575868TRLO0.1.1
08/12/2023	11:43:42	4914	143	XLON	00381575869TRLO0.1.1
08/12/2023	11:46:37	387	143	XLON	00381576186TRLO0.1.1
08/12/2023	11:47:00	387	142	CHIX	00381576246TRLO0.1.1
08/12/2023	11:47:00	274	142	XLON	00381576248TRLO0.1.1
08/12/2023	11:47:00	61	142	XLON	00381576249TRLO0.1.1
08/12/2023	11:47:00	647	142	XLON	00381576250TRLO0.1.1
08/12/2023	11:47:00	566	142	XLON	00381576251TRLO0.1.1
08/12/2023	11:47:01	387	141.8	BATE	00381576254TRLO0.1.1
08/12/2023	11:47:01	249	141.8	AQXE	00381576253TRLO0.1.1
08/12/2023	11:47:06	139	141.4	TRQX	00381576261TRLO0.1.1
08/12/2023	11:47:08	560	141.8	CHIX	00381576263TRLO0.1.1
08/12/2023	12:03:31	387	140.8	CHIX	00381577770TRLO0.1.1
08/12/2023	12:03:31	387	140.8	XLON	00381577771TRLO0.1.1
08/12/2023	12:03:31	111	140.8	XLON	00381577772TRLO0.1.1
08/12/2023	12:03:31	387	140.6	BATE	00381577773TRLO0.1.1
08/12/2023	12:11:11	49	140.4	CHIX	00381578562TRLO0.1.1
08/12/2023	12:11:11	101	140.6	CHIX	00381578563TRLO0.1.1
08/12/2023	12:11:34	95	140.4	CHIX	00381578599TRLO0.1.1
08/12/2023	12:12:28	62	140.4	CHIX	00381578693TRLO0.1.1
08/12/2023	12:13:06	63	140.4	CHIX	00381578751TRLO0.1.1
08/12/2023	12:13:52	69	140.4	CHIX	00381578832TRLO0.1.1
08/12/2023	12:43:03	663	140.6	XLON	00381581709TRLO0.1.1
08/12/2023	13:34:18	249	140.8	AQXE	00381589653TRLO0.1.1
08/12/2023	13:34:18	387	140.6	CHIX	00381589654TRLO0.1.1
08/12/2023	13:34:18	387	140.6	BATE	00381589655TRLO0.1.1
08/12/2023	13:34:18	1548	140.6	XLON	00381589656TRLO0.1.1
08/12/2023	13:35:07	387	140.4	CHIX	00381589951TRLO0.1.1
08/12/2023	13:40:42	297	141.6	CHIX	00381591280TRLO0.1.1
08/12/2023	13:40:42	46	141.6	CHIX	00381591281TRLO0.1.1
08/12/2023	14:37:22	387	141.4	CHIX	00381605540TRLO0.1.1
08/12/2023	14:37:22	476	141.4	XLON	00381605541TRLO0.1.1
08/12/2023	14:37:22	72	141.4	XLON	00381605549TRLO0.1.1
08/12/2023	14:37:22	1000	141.4	XLON	00381605548TRLO0.1.1
08/12/2023	14:37:22	737	141.4	XLON	00381605550TRLO0.1.1
08/12/2023	14:37:22	249	141.2	AQXE	00381605551TRLO0.1.1
08/12/2023	14:37:22	15	141	TRQX	00381605553TRLO0.1.1
08/12/2023	14:37:22	90	141	TRQX	00381605552TRLO0.1.1
08/12/2023	14:37:22	18	141	TRQX	00381605554TRLO0.1.1
08/12/2023	14:37:22	139	141	TRQX	00381605555TRLO0.1.1
08/12/2023	14:37:22	16	141	TRQX	00381605556TRLO0.1.1
08/12/2023	14:37:22	790	141.4	CHIX	00381605557TRLO0.1.1
08/12/2023	14:37:22	210	141.4	CHIX	00381605558TRLO0.1.1
08/12/2023	14:37:22	210	141.4	CHIX	00381605559TRLO0.1.1
08/12/2023	14:37:22	790	141.4	CHIX	00381605560TRLO0.1.1
08/12/2023	14:37:22	387	141	BATE	00381605561TRLO0.1.1
08/12/2023	14:37:22	387	141	BATE	00381605563TRLO0.1.1
08/12/2023	14:41:24	1302	141.8	CHIX	00381608047TRLO0.1.1
08/12/2023	15:20:40	774	141.4	CHIX	00381631327TRLO0.1.1
08/12/2023	15:21:59	59	142	BATE	00381631855TRLO0.1.1
08/12/2023	15:38:23	212	142	BATE	00381639214TRLO0.1.1
08/12/2023	16:05:09	19	142	XLON	00381652417TRLO0.1.1
08/12/2023	16:13:43	387	141.4	BATE	00381657230TRLO0.1.1
08/12/2023	16:13:43	387	141.4	CHIX	00381657231TRLO0.1.1
08/12/2023	16:13:43	139	141.4	TRQX	00381657232TRLO0.1.1
08/12/2023	16:13:43	1161	141.4	XLON	00381657233TRLO0.1.1
08/12/2023	16:13:43	672	141.4	XLON	00381657234TRLO0.1.1
08/12/2023	16:13:43	102	141.4	XLON	00381657235TRLO0.1.1
08/12/2023	16:13:43	249	141.4	AQXE	00381657236TRLO0.1.1
08/12/2023	16:13:53	2620	141.8	XLON	00381657339TRLO0.1.1
08/12/2023	16:14:14	440	142	CHIX	00381657505TRLO0.1.1
08/12/2023	16:14:14	683	142	CHIX	00381657506TRLO0.1.1
08/12/2023	16:14:14	1586	142	CHIX	00381657507TRLO0.1.1
08/12/2023	16:15:13	61	142	XLON	00381658009TRLO0.1.1
08/12/2023	16:15:15	387	142	CHIX	00381658023TRLO0.1.1
08/12/2023	16:17:27	387	141.6	CHIX	00381659385TRLO0.1.1
08/12/2023	16:17:27	1548	141.6	XLON	00381659386TRLO0.1.1
08/12/2023	16:18:54	428	142	XLON	00381660203TRLO0.1.1
08/12/2023	16:18:54	19	142	XLON	00381660204TRLO0.1.1
08/12/2023	16:26:05	387	141.4	BATE	00381663621TRLO0.1.1
08/12/2023	16:26:05	387	141.4	CHIX	00381663622TRLO0.1.1
08/12/2023	16:29:43	1176	141.6	XLON	00381665210TRLO0.1.1
08/12/2023	16:29:44	791	141.6	XLON	00381665226TRLO0.1.1
08/12/2023	16:29:44	1214	141.6	XLON	00381665225TRLO0.1.1
08/12/2023	16:29:44	791	141.6	XLON	00381665227TRLO0.1.1
08/12/2023	16:29:44	289	141.6	XLON	00381665228TRLO0.1.1
08/12/2023	16:29:44	441	141.6	XLON	00381665229TRLO0.1.1
08/12/2023	16:29:45	763	141.6	XLON	00381665251TRLO0.1.1
08/12/2023	16:29:45	249	141.6	XLON	00381665252TRLO0.1.1
08/12/2023	16:29:46	648	141.6	XLON	00381665258TRLO0.1.1
08/12/2023	16:29:46	236	141.6	XLON	00381665259TRLO0.1.1
08/12/2023	16:29:46	101	141.6	XLON	00381665260TRLO0.1.1
08/12/2023	16:29:47	1345	141.6	XLON	00381665270TRLO0.1.1
08/12/2023	16:29:47	1261	141.6	XLON	00381665272TRLO0.1.1
08/12/2023	16:29:48	754	141.8	AQXE	00381665294TRLO0.1.1
08/12/2023	16:29:54	242	141.8	AQXE	00381665420TRLO0.1.1
08/12/2023	16:29:57	474	141.6	XLON	00381665492TRLO0.1.1
08/12/2023	16:29:57	787	141.6	XLON	00381665493TRLO0.1.1
08/12/2023	16:29:58	1261	141.6	XLON	00381665515TRLO0.1.1
08/12/2023	16:29:59	963	141.6	XLON	00381665525TRLO0.1.1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSFLFETFVLTIIV

Date		Source	Headline
23rd May 2022	7:00 am	RNS	Transaction in Own Shares
20th May 2022	7:00 am	RNS	Transaction in Own Shares
19th May 2022	7:00 am	RNS	PDMR Notification RSU Vesting
19th May 2022	7:00 am	RNS	Transaction in Own Shares
18th May 2022	7:00 am	RNS	Transaction in Own Shares
17th May 2022	12:00 pm	RNS	PRTC to Present at UBS Healthcare Conference
17th May 2022	7:00 am	RNS	Transaction in Own Shares
16th May 2022	2:30 pm	RNS	PRTC Presents LYT-100 Data at ATS Conference
16th May 2022	7:00 am	RNS	Transaction in Own Shares
13th May 2022	7:00 am	RNS	Transaction in Own Shares
12th May 2022	7:00 am	RNS	Transaction in Own Shares
11th May 2022	7:00 am	RNS	Transaction in Own Shares
10th May 2022	7:00 am	RNS	Transaction in Own Shares
9th May 2022	7:00 am	RNS	PRTC Share Buyback Programme Commences Purchases
5th May 2022	7:00 am	RNS	PRTC Announces Share Buyback Programme Up to $50M
4th May 2022	11:35 am	RNS	Gelesis Presents GS200 Weight Loss Data at ECO
3rd May 2022	7:00 am	RNS	Total Voting Rights
29th Apr 2022	11:05 am	RNS	Gelesis Data: Therapeutic Shows Gut Health Benefit
26th Apr 2022	7:00 am	RNS	PRTC Final Results & Publication of Annual Report
13th Apr 2022	4:44 pm	RNS	PRTC's Vedanta Publishes VE303 Data
12th Apr 2022	12:05 pm	RNS	Akili Depression Data Published in AJP
12th Apr 2022	7:00 am	RNS	Glyph: 20x Oral Bioavailability of Buprenorphine
7th Apr 2022	7:00 am	RNS	Notice of Results
1st Apr 2022	7:00 am	RNS	Total Voting Rights
24th Mar 2022	7:00 am	RNS	PRTC Appoints Merck Vet to BOD & Audit Committee
17th Mar 2022	1:05 pm	RNS	Akili Adds Gaming Vet as Chief Product Officer
16th Mar 2022	10:35 am	RNS	Gelesis: Record-Breaking Plenity Prescriptions
8th Mar 2022	12:05 pm	RNS	Akili Named to World's Most Innovative Companies
18th Feb 2022	4:30 pm	RNS	Holding(s) in Company
17th Feb 2022	12:05 pm	RNS	Akili Data: Enhanced Brain Activity in Kids w/ADHD
15th Feb 2022	7:00 am	RNS	PRTC's Akili Files Registration Statement on S-4
10th Feb 2022	12:00 pm	RNS	PRTC to Present at Leerink Healthcare Conference
4th Feb 2022	7:00 am	RNS	PDMR DEALING - PURCHASE OF SHARES
31st Jan 2022	11:50 am	RNS	PRTC's Gelesis Launches Plenity Media Campaign
26th Jan 2022	12:02 pm	RNS	PRTC’s Akili to Become Public & $162M Funding
14th Jan 2022	7:00 am	RNS	PRTC's Gelesis to Debut on NYSE Today Ticker GLS
7th Jan 2022	12:00 pm	RNS	PureTech to Present at JPM Healthcare Conference
6th Jan 2022	7:00 am	RNS	LYT-100 Shows Improved AE Profile vs Pirfenidone
5th Jan 2022	12:05 pm	RNS	Gelesis Adds to BOD & Declared Effective by SEC
20th Dec 2021	7:00 am	RNS	PDMR DEALING - PURCHASE OF SHARES
16th Dec 2021	7:00 am	RNS	PRTC Provides Recap Ahead of Catalyst-Rich 2022
8th Dec 2021	12:00 pm	RNS	PRTC Presents Data at ACNP Conference For LYT-300
7th Dec 2021	12:00 pm	RNS	PRTC's Lymphatic Platform Candidate Human Study
1st Dec 2021	12:10 pm	RNS	PRTC: Gelesis' Plenity Now Broadly Available in US
1st Dec 2021	7:00 am	RNS	Total Voting Rights
18th Nov 2021	12:10 pm	RNS	PRTC's Gelesis Receives $30M Plenity Order from Ro
16th Nov 2021	12:00 pm	RNS	PRTC Publishes Previous LYT-100 MAD Study Results
15th Nov 2021	12:00 pm	RNS	PRTC Presents at Two Upcoming Investor Conferences
12th Nov 2021	12:00 pm	RNS	PRTC Presents Immunooncology Ph 1/2 Trial at SITC
11th Nov 2021	12:00 pm	RNS	FDA Grants PRTC's LYT-200 Orphan Drug Designation

Latest Share Chat

PureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

Login to your account

Quickpicks are a member only feature

Login to your account